Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.
基于Veldona的新型潜在动物药物的临床研究有望扩大VELDONA的市场。
This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025.
该临床试验的目标是到2024年底完成30名受试者的入组，试验报告将于2025年第一季度完成。
SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"), today announced it has enrolled the first subject for its Taiwanese clinical study of VELDONA-based animal drug in treating feline chronic gingivostomatitis ("FCGS"), a serious and painful chronic cat oral disease characterized by inflammation or abnormal proliferation in the oral cavity. Dosing of the first subject is expected to occur on July 26, 2024.
加利福尼亚州圣地亚哥/ACCESSWIRE/2024年7月23日/Ainos, Inc.（纳斯达克股票代码：AIMD，AIMDW）））（“Ainos” 或 “公司”），一家专注于新型人工智能即时测试（“POCT”）和低剂量干扰素疗法（“VELDONA”）的多元化医疗保健公司，今天宣布其台湾VelDONA临床研究入组了第一位受试者基于Dona的动物药物，用于治疗猫慢性牙龈炎（“FCGS”），这是一种严重而痛苦的慢性猫口腔疾病，其特征是口腔发炎或异常增生。预计将在2024年7月26日对第一名受试者进行给药。